Biogen/Idec: still a matter of size
The merger of Biogen and Idec Pharmaceuticals, announced June 23, is likely to help the two relatively isolated companies increase presence in their disease areas. The annual R&D budget for the new pharmaceutical entity, to be called Biogen Idec Inc, will be $500 million, according to company reports.
Archive for June, 2003
105699417737921728
June 30, 2003
95828384
June 19, 2003The State of Biotechnology
Researchers, government officials and industry executives will gather this weekend in Washington for the Biotechnology Industry Organization’s annual convention. Topics to be addressed at BIO 2003 range from science and regulatory affairs to bioethics and homeland security.
95828305
June 19, 2003Coffee Plants Can Produce Less Caffeine
Researchers say they have genetically engineered coffee plants that have 70 percent less caffeine than usual in their leaves. The crucial question for brewing coffee — whether beans from those plants will have less caffeine — won’t be known for three to four years when the plants mature
95828261
June 19, 2003Pfizer’s Outlook Improves
Having spent $5 billion on research and development in 2002, Pfizer (NYSE: PFE) is king of the drug world. And with its $60 billion Pharmacia merger completed in April, the king just got fatter
95828216
June 19, 2003Schering’s Dr. Feelbetter?
Fred Hassan is out to revive the drugmaker. It’s a big job
95828167
June 19, 2003FDA approves first nasal mist flu vaccine – Jun. 18, 2003
Most people who avoid flu shots because they fear needles will not have that excuse this season. The Food and Drug administration has approved a flu vaccine that is delivered by a squirt up the nose instead of a shot in the arm.
FDA approves first nasal mist flu vaccine
June 19, 2003Most people who avoid flu shots because they fear needles will not have that excuse this season. The Food and Drug administration has approved a flu vaccine that is delivered by a squirt up the nose instead of a shot in the arm.
95828125
June 19, 2003Microsoft loses No. 2 ranking in market value to drug maker
Microsoft has lost its status as the world’s second-largest corporation to drug maker Pfizer due to slowing sales growth that caused it to miss out on this year’s stock-market rally.
Microsoft loses No. 2 ranking in market value to drug maker
June 19, 2003Microsoft has lost its status as the world’s second-largest corporation to drug maker Pfizer due to slowing sales growth that caused it to miss out on this year’s stock-market rally.
95825917
June 19, 2003Report Says More Farmers Don’t Follow Biotech Rules
A new study, drawn from government data, shows that more farmers are failing to comply with standards governing the planting of genetically modified corn than the industry has claimed.
Nearly one-fifth of farms growing the main type of genetically engineered corn, BT corn, are violating government rules aimed at preserving the usefulness of the corn, a consumer group said yesterday.
